Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

5.30USD
8:02pm BST
Change (% chg)

$-0.03 (-0.56%)
Prev Close
$5.33
Open
$5.33
Day's High
$5.36
Day's Low
$5.22
Volume
25,849
Avg. Vol
60,476
52-wk High
$15.38
52-wk Low
$4.74

Select another date:

Mon, Jun 25 2018

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

UPDATE 1-Merrimack to scrap development of pancreatic cancer treatment

June 25 Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Merrimack to scrap development of pancreatic cancer treatment

June 25 Merrimack Pharmaceuticals Inc said on Monday it would discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

Select another date: